JP Patent

JP7495345B2 — 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画

Assigned to Merck Patent GmbH · Expires 2024-06-04 · 2y expired

What this patent protects

Patent listed against Leustatin.

Drugs covered by this patent

Leustatin (CLADRIBINE)

Patent Metadata

Patent number: JP7495345B2
Jurisdiction: JP
Classification: —
Expires: 2024-06-04
Drug substance claim: No
Drug product claim: No
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.